Xencor Senior VP Disposes of $31,676 in Stock as Company Advances Royalty and Pipeline Plans
Xencor Inc. reported an insider sale by its Senior Vice President and Chief Scientific Officer, alongside disclosures of restricted stock units and option awards. The company is managing a U.S. royalty dispute over Ultomiris while extending its U.S. royalty term until December 2028 and plans a busy 2026 clinical agenda for its XmAb pipeline.